Global Vaccines Access Initiative (Global VAX or GLOVAX) is an intervention by the United States of America funded through U.S. Agency for International Development (USAID) and implemented by U.S. Pharmacopeia Convention (USP) to support COVID-19 vaccination.
Nigeria was selected as one of the six (6) African countries to participate as “spokes” in WHO’s global mRNA transfer technology hub needed to produce mRNA vaccines on the African continent. This led to the intervention by USAID to help Nigeria in particular NAFDAC to develop the necessary operating procedures and know-how to manufacture mRNA vaccines at scale and according to international standards and also assistance in Technical Areas/Regulatory Functions through the USP PQM+/Glovax program.
The program enhanced technical competencies of laboratory employees in Quality control of vaccines and other Biologicals. The staff of VBM-LSD significantly benefitted from the USP PQM+/Glovax program.
